BDBM493072 2-Cyano-N-((1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)methyl)ethanesulfonamide::US10981911, Example 13

SMILES O=S(=O)(CCC#N)NCc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1

InChI Key InChIKey=ZRWAPJQBKMIZOF-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 493072   

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493072(US10981911, Example 13 | 2-Cyano-N-((1-((1r,4r)-4-...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493072(US10981911, Example 13 | 2-Cyano-N-((1-((1r,4r)-4-...)
Affinity DataIC50: 7.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493072(US10981911, Example 13 | 2-Cyano-N-((1-((1r,4r)-4-...)
Affinity DataIC50: 651nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493072(US10981911, Example 13 | 2-Cyano-N-((1-((1r,4r)-4-...)
Affinity DataIC50: 3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails
US Patent